37 related articles for article (PubMed ID: 36309672)
21. Prebiopsy Biparametric MRI for Clinically Significant Prostate Cancer Detection With PI-RADS Version 2: A Multicenter Study.
Choi MH; Kim CK; Lee YJ; Jung SE
AJR Am J Roentgenol; 2019 Apr; 212(4):839-846. PubMed ID: 30779662
[TBL] [Abstract][Full Text] [Related]
22. Which scores need a core? An evaluation of MR-targeted biopsy yield by PIRADS score across different biopsy indications.
Sathianathen NJ; Konety BR; Soubra A; Metzger GJ; Spilseth B; Murugan P; Weight CJ; Ordonez MA; Warlick CA
Prostate Cancer Prostatic Dis; 2018 Nov; 21(4):573-578. PubMed ID: 30038389
[TBL] [Abstract][Full Text] [Related]
23. MRI in early prostate cancer detection: how to manage indeterminate or equivocal PI-RADS 3 lesions?
Schoots IG
Transl Androl Urol; 2018 Feb; 7(1):70-82. PubMed ID: 29594022
[TBL] [Abstract][Full Text] [Related]
24. Quantitation of hypoechoic lesions for the prediction and Gleason grading of prostate cancer: a prospective study.
Lee KS; Koo KC; Chung BH
World J Urol; 2018 Jul; 36(7):1059-1065. PubMed ID: 29508049
[TBL] [Abstract][Full Text] [Related]
25. Risk of Clinically Significant Prostate Cancer Associated With Prostate Imaging Reporting and Data System Category 3 (Equivocal) Lesions Identified on Multiparametric Prostate MRI.
Sheridan AD; Nath SK; Syed JS; Aneja S; Sprenkle PC; Weinreb JC; Spektor M
AJR Am J Roentgenol; 2018 Feb; 210(2):347-357. PubMed ID: 29112469
[TBL] [Abstract][Full Text] [Related]
26. Sub-differentiating equivocal PI-RADS-3 lesions in multiparametric magnetic resonance imaging of the prostate to improve cancer detection.
Hansen NL; Koo BC; Warren AY; Kastner C; Barrett T
Eur J Radiol; 2017 Oct; 95():307-313. PubMed ID: 28987685
[TBL] [Abstract][Full Text] [Related]
27. Prebiopsy mp-MRI Can Help to Improve the Predictive Performance in Prostate Cancer: A Prospective Study in 1,478 Consecutive Patients.
Wang R; Wang J; Gao G; Hu J; Jiang Y; Zhao Z; Zhang X; Zhang YD; Wang X
Clin Cancer Res; 2017 Jul; 23(14):3692-3699. PubMed ID: 28143868
[No Abstract] [Full Text] [Related]
28. The Prostate Health Index adds predictive value to multi-parametric MRI in detecting significant prostate cancers in a repeat biopsy population.
Gnanapragasam VJ; Burling K; George A; Stearn S; Warren A; Barrett T; Koo B; Gallagher FA; Doble A; Kastner C; Parker RA
Sci Rep; 2016 Oct; 6():35364. PubMed ID: 27748407
[TBL] [Abstract][Full Text] [Related]
29. Visibility of prostate cancer on transrectal ultrasound during fusion with multiparametric magnetic resonance imaging for biopsy.
van de Ven WJ; Sedelaar JP; van der Leest MM; Hulsbergen-van de Kaa CA; Barentsz JO; Fütterer JJ; Huisman HJ
Clin Imaging; 2016; 40(4):745-50. PubMed ID: 27317220
[TBL] [Abstract][Full Text] [Related]
30. NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016.
Carroll PR; Parsons JK; Andriole G; Bahnson RR; Castle EP; Catalona WJ; Dahl DM; Davis JW; Epstein JI; Etzioni RB; Farrington T; Hemstreet GP; Kawachi MH; Kim S; Lange PH; Loughlin KR; Lowrance W; Maroni P; Mohler J; Morgan TM; Moses KA; Nadler RB; Poch M; Scales C; Shaneyfelt TM; Smaldone MC; Sonn G; Sprenkle P; Vickers AJ; Wake R; Shead DA; Freedman-Cass DA
J Natl Compr Canc Netw; 2016 May; 14(5):509-19. PubMed ID: 27160230
[TBL] [Abstract][Full Text] [Related]
31. Assessment of PI-RADS v2 for the Detection of Prostate Cancer.
Kasel-Seibert M; Lehmann T; Aschenbach R; Guettler FV; Abubrig M; Grimm MO; Teichgraeber U; Franiel T
Eur J Radiol; 2016 Apr; 85(4):726-31. PubMed ID: 26971415
[TBL] [Abstract][Full Text] [Related]
32. PI-RADS version 2: what you need to know.
Barrett T; Turkbey B; Choyke PL
Clin Radiol; 2015 Nov; 70(11):1165-76. PubMed ID: 26231470
[TBL] [Abstract][Full Text] [Related]
33. Relationship Between Prebiopsy Multiparametric Magnetic Resonance Imaging (MRI), Biopsy Indication, and MRI-ultrasound Fusion-targeted Prostate Biopsy Outcomes.
Meng X; Rosenkrantz AB; Mendhiratta N; Fenstermaker M; Huang R; Wysock JS; Bjurlin MA; Marshall S; Deng FM; Zhou M; Melamed J; Huang WC; Lepor H; Taneja SS
Eur Urol; 2016 Mar; 69(3):512-7. PubMed ID: 26112001
[TBL] [Abstract][Full Text] [Related]
34. Is a visible (hypoechoic) lesion at biopsy an independent predictor of prostate cancer outcome?
Nakano Junqueira VC; Zogbi O; Cologna A; Dos Reis RB; Tucci S; Reis LO; Westphalen AC; Muglia VF
Ultrasound Med Biol; 2012 Oct; 38(10):1689-94. PubMed ID: 22920545
[TBL] [Abstract][Full Text] [Related]
35. Combined multiparametric MRI and targeted biopsies improve anterior prostate cancer detection, staging, and grading.
Ouzzane A; Puech P; Lemaitre L; Leroy X; Nevoux P; Betrouni N; Haber GP; Villers A
Urology; 2011 Dec; 78(6):1356-62. PubMed ID: 21840577
[TBL] [Abstract][Full Text] [Related]
36. Echogenicity of prostate cancer correlated with histologic grade and stromal fibrosis: endorectal US studies.
Rifkin MD; McGlynn ET; Choi H
Radiology; 1989 Feb; 170(2):549-52. PubMed ID: 2643148
[TBL] [Abstract][Full Text] [Related]
37. Usefulness of grayscale values of hypoechoic lesions matched with target lesions observed on magnetic resonance imaging for the prediction of clinically significant prostate cancer.
Kim DG; Yoo JW; Koo KC; Chung BH; Lee KS
BMC Urol; 2022 Oct; 22(1):164. PubMed ID: 36309672
[TBL] [Abstract][Full Text] [Related]
[Previous] [New Search]
